Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Lewiecki, E. Michael [1 ]
Dinavahi, Rajani V. [2 ]
Lazaretti-Castro, Marise [3 ]
Ebeling, Peter R. [4 ]
Adachi, J. [5 ]
Miyauchi, Akimitsu [6 ]
Gielen, Evelien [7 ]
Milmont, Cassandra E. [2 ]
Libanati, Cesar [8 ]
Grauer, Andreas [2 ]
机构：
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Monash Univ, Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON, Canada
[6] Miyauchi Med Ctr, Osaka, Japan
[7] Univ Hosp Leuven, Leuven, Belgium
[8] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Denosumab Among Subjects with Mild-to-Moderate Chronic Kidney Disease (CKD) in the "Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months" Extension Study
    Broadwell, Aaron
    Ebeling, Peter R.
    Franek, Edward
    Goemaere, Stefan
    Wagman, Rachel B.
    Yin, Xiang
    Yue, Susan
    Miller, Paul D.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [22] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 ARCH Study (Active-contRolled fraCture study in postmenopausal women with osteoporosis at High risk).
    Saag, Kenneth G.
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S54 - S55
  • [23] FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy E.
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (07) : 1219 - 1226
  • [24] FRAME STUDY: THE FOUNDATION EFFECT OF REBUILDING BONE WITH ONE YEAR OF ROMOSOZUMAB LEADS TO CONTINUED LOWER FRACTURE RISK AFTER TRANSITION TO DENOSUMAB
    Cosman, F.
    Crittenden, D. B.
    Ferrari, S.
    Khan, A.
    Lane, N. E.
    Lippuner, K.
    Matsumoto, T.
    Milmont, C. E.
    Libanati, C.
    Grauer, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 217 - 218
  • [25] EFFECTS OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AFTER 2 AND 12 MONTHS ASSESSED BY MICRO COMPUTED TOMOGRAPHY AND HISTOMORPHOMETRY ON ILIAC CREST BONE BIOPSIES
    Chavassieuxl, P.
    Chapurlatl, R.
    Roux, J. -P.
    Portero-Muzy, N.
    Garcia, P.
    Brown, J. P.
    Horlait, S.
    Libanati, C.
    Boyce, R.
    Wang, A.
    Grauer, A.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S59 - S59
  • [26] FRAME STUDY: THE FOUNDATION EFFECT OF REBUILDING BONE WITH ONE YEAR OF ROMOSOZUMAB LEADS TO CONTINUED LOWER FRACTURE RISK AFTER TRANSITION TO DENOSUMAB
    Cosman, F.
    Crittenden, D. B.
    Ferrari, S.
    Khan, A.
    Lanes, N. E.
    Lippuner, K.
    Matsumoto, T.
    Milisiont, C. E.
    Libanati, C.
    Grauers, A.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S268 - S268
  • [27] Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
    Chavassieux, Pascale
    Chapurlat, Roland
    Portero-Muzy, Nathalie
    Roux, Jean-Paul
    Garcia, Pedro
    Brown, Jacques P.
    Libanati, Cesar
    Boyce, Rogely W.
    Wang, Andrea
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (09) : 1597 - 1608
  • [28] FRAME Study: The Foundation Effect of Rebuilding Bone With One Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman, Felicia
    Crittenden, Daria B.
    Ferrari, Serge
    Khan, Aliya
    Lane, Nancy
    Lippuner, Kurt
    Matsumoto, Toshio
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S37 - S38
  • [29] The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study
    Inose, Hiroyuki
    Ariga, Akane
    Motoyoshi, Takayuki
    Fukushima, Kazuyuki
    Tomizawa, Shoji
    Kato, Tsuyoshi
    Takahashi, Kunihiko
    Yoshii, Toshitaka
    Okawa, Atsushi
    JBMR PLUS, 2022, 6 (07)
  • [30] T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
    Cosman, Felicia
    Lewiecki, E. Michael
    Ebeling, Peter R.
    Hesse, Eric
    Napoli, Nicola
    Crittenden, Daria B.
    Rojeski, Maria
    Yang, Wenjing
    Libanati, Cesar
    Ferrari, Serge
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345